About the TAPUR Study
The Targeted Agent and Profiling Utilization Registry (TAPUR) Study is a non-randomized clinical trial that aims to describe the performance (both safety and efficacy) of commercially available, targeted anticancer drugs prescribed for treatment of patients with advanced cancer that has a potentially actionable genomic variant. The study provides approved targeted therapies that are contributed to the program by collaborating pharmaceutical companies, catalogues the choice of genomic profiling test by clinical oncologists and aims to learn about the utility of registry data to develop hypotheses for additional clinical trials. To find responses to commonly asked questions, please visit our FAQ page and review our patient brochure.
Study participants get access to targeted drugs matched to the genomic profiles of their tumors.
Physician investigators receive assistance interpreting genomic test results and identifying appropriate treatments.
Cancer community learns about new uses of targeted anti-cancer drugs for patients who have exhausted current options.
Pharmaceutical companies get data on use of drugs for possible new cancer indications already being used in clinical practice.
Regulators get data about adverse events and other outcomes.
TAPUR Study News
ASCO announced that 105 participants have are now enrolled on the TAPUR Study. An additional 25 clinical sites are being brought onto the study, increasing the total number of enrolling TAPUR locations to 63 sites. ASCO also announced plans to decrease the enrollment age from 18 to 12 years to extend the opportunity for participation to adolescent patients with advanced cancer.
ASCO announced that Bayer and Merck are the most recent companies to sign on to provide study drugs at no cost to patients enrolled in the TAPUR joining six other companies in ASCO’s first-ever clinical trial. Since opening on March 14, 2016, 18 participants have enrolled and are receiving study treatment, and 31 more have provided consent and are in, or have completed, the screening process.
ASCO has begun recruiting patients with advanced cancer for its first-ever clinical trial, the Targeted Agent and Profiling Utilization Registry (TAPUR) study. The trial will evaluate molecularly-targeted cancer drugs and collect data on clinical outcomes to help learn additional uses of these drugs outside of indications already approved by the Food and Drug Administration (FDA). Patients enrolled in the study will have access to these cancer drugs at no cost.
Network of Centers
TAPUR is now enrolling patients at cancer centers and networks across the country. Additional sites will be brought on throughout 2016 and 2017.